Know Cancer

forgot password

Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy

18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy

Inclusion Criteria:

- Age ≥ 18 years at time of consent

- Patients planning to undergo radiation therapy for primary or recurrent carcinomas of
the lung or cancer that is metastatic to the lung.

- Patients who are to receive 30 Gy or more of external beam radiation therapy.

- Patients who are able to tolerate flexible bronchoscopy.

- Patients with life expectancy of at least 12 months.

- Patients for whom the physician is able to identify suitable implantation sites for
the anchored transponders on a recent (within the past 8 weeks) CT scan.

- Patients who are able to comply with the protocol.

Exclusion Criteria:

- Patients with implants in the chest region that contain metal or conductive materials
(e.g., metal implants, rods, or plates) which Calypso Medical considers will
interfere with the Calypso System's electromagnetic localization.

- Patients with active implanted devices, such as pacemakers, defibrillators, and drug
infusion pumps since the effect of the Calypso System operation on these devices is

- Patients with active infections.

- Patients with bronchiectasis in the lobe of the intended implantation sites.

- Patients with a history of hypersensitivity to nickel.

- Patients whose lung tumors are being monitored with MR imaging (MR imaging of the
anchored transponders is safe but yields an image artifact around the anchored

- Patients with any other medical condition or laboratory value that would, at the
discretion of the investigator, preclude the patient from participation in this
clinical study.

- For clinical study sites in Germany only the following items are additional specific
exclusion criteria:

- Positive pregnancy test.

- Patients requiring additional therapies for the lung, such as brachytherapy,
electrosurgical procedures, cryoablation and laser vaporization as stated in the
Precautions section in the Instructions for Use.

- Patients in whom real-time tracking with the Calypso System is not expected to
be possible due to patient size.

- Patients enrolled in any other clinical studies the investigator believes to be in
conflict with this investigation.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Localization using the Calypso system.

Outcome Description:

The primary endpoint of localization will be assessed within approximately 1-2 weeks following implantation at the time radiation treatment is initiated and the ability to localize the target is confirmed. Additionally, participants will be followed for approximately one year after implantation for assessment of safety outcomes.

Outcome Time Frame:

1-2 weeks following implantation

Safety Issue:



United States: Food and Drug Administration

Study ID:

CMT - 01-10



Start Date:

October 2010

Completion Date:

January 2014

Related Keywords:

  • Lung Cancer
  • Anchored Beacon Transponder
  • Anchored Transponder
  • Lung cancer
  • Calypso system
  • Realtime tracking
  • Lung Neoplasms



Washington UniversitySt. Louis, Missouri  63110
Radiological Associates of SacramentoSacramento, California  95816
21st Century OncologyCape Coral, Florida  33990
Cancer Treatment Centers of America (CTCA)Tulsa, Oklahoma